Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

Key Players: Major companies operating in the molecular spectroscopy market are Thermo Fisher Scientific, Inc, Merck KGaA, PerkinElmer Inc., Agilent Technologies, Inc, Bruker, Horiba, Ltd, Shimadzu ...

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...

German science and technology company Merck on Thursday forecast its net sales to be in the range of €21.5 billion ($23.2 ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...